短期减少膳食麸质改善代谢功能障碍相关脂肪性肝病:一项随机对照概念验证研究
该6周概念验证随机对照试验将45例经活检证实的MASLD患者按1:1分为无ATI(麸质)饮食组和德国营养学会推荐均衡饮食对照组,评估CAP、BMI、HOMA-IR及CLDQ-NASH评分变化。无ATI饮食组6周时BMI、CAP、HOMA-IR均显著下降,两组第6周CAP平均差异为30.5 dB/m(p=0.039),且仅无ATI饮食组CLDQ-NASH总分显著改善(p=0.013)。作者认为短期无ATI饮食可显著改善肝脏及代谢指标和患者报告结局,耐受性良好,需更大规模随访研究证实。
要点
- 无ATI饮食组6周时BMI(p=0.018)、CAP(p=0.018)、HOMA-IR(p=0.042)均显著下降。
- 两组第6周CAP平均差异为30.5 dB/m(p=0.039),无ATI饮食组变化值显著更高(p=0.043)。
- 仅无ATI饮食组CLDQ-NASH各域及总分显著改善(总分p=0.013)。
核心结论
- 短期无ATI饮食可显著改善肝脏及代谢参数以及患者报告结局,耐受性良好。
- 作者认为需要更大规模的随访研究来证实这些发现。
研究设计与样本
- 6周、概念验证、1:1随机对照试验,评估无ATI饮食的影响。
- 对照组遵循德国营养学会推荐的均衡饮食。
- 共连续纳入45例经活检证实的MASLD患者,干预组21例,对照组24例。
- 评估指标包括CAP、BMI、HOMA-IR,患者报告结局采用CLDQ-NASH问卷。
- 临床试验注册号NCT04066400。
主要发现
- 无ATI饮食组6周时BMI显著下降(p=0.018)。
- 无ATI饮食组6周时CAP显著下降(p=0.018)。
- 无ATI饮食组6周时HOMA-IR显著下降(p=0.042)。
- 两组第6周CAP平均差异为30.5 dB/m(p=0.039),无ATI饮食组变化值显著更高(p=0.043)。
- 仅无ATI饮食组CLDQ-NASH各域显著改善(总分p=0.013)。
临床怎么用
- 作者认为短期无ATI饮食可显著改善肝脏及代谢参数以及患者报告结局,耐受性良好。
- 作者认为需要更大规模的随访研究来证实这些发现。
局限性
- 作者认为需要更大规模的随访研究来证实这些发现。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The current management of metabolic dysfunction-associated steatotic liver disease (MASLD) relies on lifestyle intervention. Prior studies have shown that nutritional wheat amylase trypsin inhibitors (ATI) activate toll-like receptor 4 on intestinal myeloid cells to enhance intestinal and extra-intestinal inflammation, including the promotion of murine MASLD, insulin resistance and liver fibrosis. AIMS: We aimed to assess the impact of ATI (gluten)-free diet in liver as well as metabolic parameters of biopsy-proven MASLD patients. METHODS: We performed a 6-week, proof-of-concept 1:1 randomised controlled trial of an ATI-free diet. The controls followed a balanced diet recommended by the German Nutrition Society. We assessed changes in controlled attenuation parameter (CAP), body mass index (BMI) and homeostatic model assessment of insulin resistance (HOMA-IR). Patient-reported outcomes were assessed by the CLDQ-NASH questionnaire. Forty-five patients were consecutively enrolled (21 in the intervention arm and 24 in the control arm). RESULTS: Three patients from each arm discontinued the study. In the ATI-free diet group, a significant decrease in BMI (p = 0.018), CAP (p = 0.018) and HOMA-IR (p = 0.042) was observed at 6 weeks. The mean difference in CAP between the two arms at week 6 was 30.5 dB/m (p = 0.039), with a delta significantly higher in the ATI-free diet group (p = 0.043). Only an ATI-free diet could achieve a significant improvement in CLDQ-NASH domains (p value for total scoring: 0.013). CONCLUSIONS: A short-term ATI-free diet leads to significant improvements in liver and metabolic parameters, as well as patient-reported outcomes with good tolerability. A larger follow-up study is justified to corroborate these findings. CLINICAL TRIAL NUMBER: NCT04066400.
引用
- Armandi A, Bespaljko H, Mang A, et al. Short-term reduction of dietary gluten improves metabolic-dysfunction associated steatotic liver disease: A randomised, controlled proof-of-concept study. Aliment Pharmacol Ther. 2024. PMID: 38462919. doi:10.1111/apt.17941
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。